Once-daily insulin detemir added to oral antidiabetic drugs results in less weight gain and a trend for reduced hypoglycaemia in comparison to NPH insulin in Japanese patients with type 2 diabetes

被引：0

作者：

Tajima, N.

Iwamoto, Y.

Kaku, K.

Kawamori, R.

Nishida, T.

Kobayashi, M.

机构：

[1] Jikei Univ, Sch Med, Tokyo, Japan

[2] Tokyo Womens Med Univ, Dept Med, Tokyo, Japan

[3] Kawasaki Med Sch, Diabet & Emdocrine Div, Okayama, Japan

[4] Juntendo Univ, Dept Med, Tokyo, Japan

[5] Novo Nordisk Pharm Ltd, Tokyo, Japan

[6] Toyama Univ, Toyama 930, Japan

来源：

DIABETOLOGIA | 2006年 / 49卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0996

引用

页码：609 / 609

页数：1

共 50 条

[1] Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes
Philis-Tsimikas, Athena
Charpentier, Guillaume
Clauson, Per
Ravn, Gabriela Martinez
Roberts, Victor Lawrence
Thorsteinsson, Birger
CLINICAL THERAPEUTICS, 2006, 28 (10) : 1569 - 1581
[2] Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients -: The PREDICTIVE™ BMI clinical trial
Montanana, C. Fajardo
Herrero, C. Hernandez
Fernandez, M. Rivas
DIABETIC MEDICINE, 2008, 25 (08) : 916 - 923
[3] Comparison of once-daily detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes (vol 28, pg 1569, 2006)
不详
CLINICAL THERAPEUTICS, 2006, 28 (11) : 1967 - 1967
[4] Less weight gain and hypoglycaemia with once-daily insulin detemir than with NPH insulin in basal-bolus therapy of overweight type 2 diabetes patients: The PREDICTIVE-BMT trial
Montanana, C. Fajardo
Herrero, C. Hernandez
Fernandez, M. Rivas
DIABETOLOGIA, 2007, 50 : S404 - S404
[5] Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes
Vora, J.
Caputo, S.
Damci, T.
Orozco-Beltran, D.
Pan, C.
Svendsen, A. L.
Solje, K. S.
Khunti, K.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2014, 39 (02) : 136 - 143
[6] Use of insulin deternir once-daily results in less weight gain compared with the use of NPH insulin, particularly in obese subjects with type 2 diabetes
Philis-Tsimikas, A.
Koenen, C.
Pedersen, C. B.
Thorsteinsson, B.
DIABETOLOGIA, 2007, 50 : S404 - S404
[7] Insulin detemir results in less weight gain than NPH insulin when added to oral agents in type 2 diabetes, with this advantage increasing with baseline obesity
Hermansen, K
Tamer, SC
DIABETOLOGIA, 2005, 48 : A4 - A5
[8] Effect of Once-Daily Detemir vs NPH Insulin on Body Weight and Metabolic Control When Added to OADs in Type 2 Diabetes
Catrinoiu, Doina
Veresiu, Ioan Andrei
Botnariu, Eosefina Gina
DIABETES, 2009, 58 : A521 - A521
[9] Study of once-daily Levemir (SOLVE™) 3: safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral antidiabetic therapy
Ross, S. A.
Dzida, G.
Ligthelm, R. J.
DIABETOLOGIA, 2011, 54 : S422 - S423
[10] Detemir as a once-daily basal insulin in type 2 diabetes
Nelson, Scott E.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2011, 3 : 27 - 37

← 1 2 3 4 5 →